PACS Group (NYSE:PACS) Director Sells $6,432,253.26 in Stock

PACS Group, Inc. (NYSE:PACS) Director Mark Hancock sold 144,318 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $44.57, for a total value of $6,432,253.26. Following the sale, the director directly owned 53,674,566 shares of the company’s stock, valued at $2,392,275,406.62. The trade was a 0.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Hancock also recently made the following trade(s):

• On Tuesday, September 15th, Mark Hancock sold 155,682 shares of PACS Group stock. The stock was sold at an average price of $42.47, for a total value of $6,611,814.54.
• On Thursday, July 9th, Mark Hancock sold 4,966 shares of PACS Group stock. The shares were sold at an average price of $45.06, for a total value of $223,767.96.
• On Wednesday, July 8th, Mark Hancock sold 20,338 shares of PACS Group stock. The shares were sold at an average price of $45.07, for a total value of $916,633.66.
• On Monday, July 6th, Mark Hancock sold 142,163 shares of PACS Group stock. The shares were sold at an average price of $45.33, for a total value of $6,444,248.79.
• On Thursday, July 2nd, Mark Hancock sold 12,825 shares of PACS Group stock. The stock was sold at an average price of $45.01, for a total value of $577,253.25.
• On Wednesday, July 1st, Mark Hancock sold 6,080 shares of PACS Group stock. The stock was sold at an average price of $45.02, for a total transaction of $273,721.60.
• On Friday, June 26th, Mark Hancock sold 61,931 shares of PACS Group stock. The shares were sold at an average price of $40.50, for a total transaction of $2,508,205.50.
• On Thursday, June 25th, Mark Hancock sold 138,069 shares of PACS Group stock. The shares were sold at an average price of $40.33, for a total transaction of $5,568,322.77.
• On Wednesday, June 17th, Mark Hancock sold 63,680 shares of PACS Group stock. The stock was sold at an average price of $35.31, for a total transaction of $2,248,540.80.

PACS Group Stock Performance

PACS stock traded down $2.54 during mid-day trading on Tuesday, hitting $42.01. The company had a trading volume of 1,011,870 shares, compared to its average volume of 905,184. The firm has a market cap of $6.65 billion, a PE ratio of 24.42, a price-to-earnings-growth ratio of 1.40 and a beta of -0.13. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.91 and a current ratio of 0.91. PACS Group, Inc. has a 12 month low of $10.31 and a 12 month high of $49.49. The stock’s fifty day moving average price is $44.74 and its two-hundred day moving average price is $39.12.

PACS Group (NYSE:PACS) last released its earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.54 by $0.09. PACS Group had a net margin of 4.85% and a return on equity of 29.55%. The firm had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $1.41 billion. On average, analysts forecast that PACS Group, Inc. will post 2.13 earnings per share for the current fiscal year.

Institutional Trading of PACS Group

Institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP boosted its holdings in PACS Group by 370.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 780,159 shares of the company’s stock worth $25,051,000 after buying an additional 614,250 shares during the period. 8 Knots Management LLC bought a new stake in PACS Group during the 4th quarter valued at $23,421,000. Sei Investments Co. raised its holdings in PACS Group by 7.4% during the 1st quarter. Sei Investments Co. now owns 370,501 shares of the company’s stock valued at $11,900,000 after acquiring an additional 25,462 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in shares of PACS Group by 44.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 288,718 shares of the company’s stock worth $9,274,000 after acquiring an additional 89,067 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of PACS Group during the second quarter worth $8,196,000.

Key PACS Group News

Here are the key news stories impacting PACS Group this week:

• Positive Sentiment: Investor Steven Cress highlighted PACS Group as a highly rated stock he owns, reinforcing the bullish case for the skilled-nursing and post-acute-care operator. Behind The Portfolio: Why Steven Cress Owns This Top-Rated Stock
• Positive Sentiment: Analyst sentiment remains favorable: PACS has a consensus “Moderate Buy” rating and an average price target of $58.80, above recent trading levels. Truist, Oppenheimer, UBS and JPMorgan have recently set targets ranging from $57 to $62. The company also exceeded second-quarter earnings and revenue expectations, reporting adjusted earnings of $0.63 per share versus the $0.54 consensus and revenue of $1.43 billion versus $1.41 billion.
• Neutral Sentiment: PACS announced that CEO and Chairman Jason Murray, CFO Carey Hendrickson and COO Josh Jergensen will present at the Jefferies Healthcare Services and Technology Conference on September 15. Investors may look for updates on operations, growth plans and the company’s outlook. PACS Group to Present at the 2026 Jefferies Healthcare Services and Technology Conference
• Negative Sentiment: CEO Jason Murray continued selling shares under a pre-arranged Rule 10b5-1 plan, including 317 shares at $45.03 and earlier sales of 10,529 shares at $45.23 and 8,771 shares at $45.16. The sales can weigh on sentiment, although they represent a very small portion of his roughly 54.6 million remaining shares and do not necessarily signal deteriorating business prospects. Insider Selling: PACS Group CEO Sells 317 Shares

Analyst Ratings Changes

PACS has been the subject of several research reports. JPMorgan Chase & Co. increased their price objective on PACS Group from $47.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, September 4th. Zacks Research lowered PACS Group from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 9th. Oppenheimer upped their price target on PACS Group from $48.00 to $57.00 and gave the company an “outperform” rating in a research report on Monday, August 10th. Truist Financial set a $62.00 price target on PACS Group in a research note on Wednesday, September 2nd. Finally, Royal Bank Of Canada lifted their price objective on PACS Group from $52.00 to $57.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, PACS Group has an average rating of “Moderate Buy” and a consensus target price of $58.80.

About PACS Group

PACS Group, Inc is a U.S. healthcare services company that operates skilled nursing and post-acute care facilities. Its facilities provide short-term rehabilitation, long-term skilled nursing, nursing care, and related clinical services for patients recovering from illness, injury, surgery, or hospitalization.

The company’s broader care offerings may include assisted living, memory care, behavioral health, and other specialized post-acute services, depending on the facility and market.